Literature DB >> 8308926

Germline p53 gene mutations in subsets of glioma patients.

A P Kyritsis1, M L Bondy, M Xiao, E L Berman, J E Cunningham, P S Lee, V A Levin, H Saya.   

Abstract

BACKGROUND: Heritable germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome, occasionally in nonfamilial malignancies such as multifocal osteosarcoma, in a small subgroup of young patients with two or more primary malignancies, and in patients with sporadic breast carcinoma. We recently reported that multifocal gliomas are frequently associated with other primary malignancies, and we hypothesized that genetic alterations may account for this phenomenon.
PURPOSE: We examined the frequency of germline p53 gene mutations in patients with glioma and either multifocality of lesions, history of an additional primary (different) malignancy, or a family history of cancer.
METHODS: Lymphocytes from 51 glioma patients were analyzed for germline p53 gene mutations using RNA-polymerase chain reaction analysis, single-strand conformation polymorphism, and gene sequencing techniques.
RESULTS: Germline p53 gene mutations were detected in six of 19 patients with multifocal glioma, including two with family history of cancer, one with another primary malignancy, and two with all three risk factors; one of four patients with unifocal glioma, another primary malignancy, and a family history of cancer; and two of 15 patients with unifocal glioma and a family history of cancer but no second malignancies. No mutations were detected in the patient with unifocal glioma and another malignancy or in the 12 control patients with unifocal glioma and no second malignancies or family history of cancer. Patients having mutations were younger than other patients in the same group.
CONCLUSIONS: Germline p53 mutations are frequent in patients with multifocal glioma, glioma and another primary malignancy, and glioma associated with a family history of cancer, particularly if these factors are combined. IMPLICATIONS: Relatives at high risk can be identified for genetic counseling, early cancer detection, and possible enrollment in chemoprevention trials.

Entities:  

Mesh:

Year:  1994        PMID: 8308926     DOI: 10.1093/jnci/86.5.344

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

1.  Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.

Authors:  Lindsay B Robertson; Georgina N Armstrong; Bianca D Olver; Amy L Lloyd; Sanjay Shete; Ching Lau; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Amanda Lynn Rynearson; Amanda L Rynerason; Margaret Wrensch; Lucie McCoy; John K Wienkce; Bridget McCarthy; Faith Davis; Nicholas A Vick; Christoffer Johansen; Hanne Bødtcher; Siegal Sadetzki; Revital Bar-Sade Bruchim; Galit Hirsh Yechezkel; Ulrika Andersson; Beatrice S Melin; Melissa L Bondy; Richard S Houlston
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

2.  p53 protein in pediatric malignant astrocytomas: a study of 21 patients.

Authors:  M B Bhattacharjee; J M Bruner
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

3.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

Review 4.  Genetic alterations of brain tumors.

Authors:  K von Ammon; U Roelcke
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  MR imaging correlates of survival in patients with high-grade gliomas.

Authors:  Whitney B Pope; James Sayre; Alla Perlina; J Pablo Villablanca; Paul S Mischel; Timothy F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

6.  Absence of germline and somatic p53 alterations in children with sporadic brain tumors.

Authors:  C Portwine; S Chilton-MacNeill; C Brown; E Sexsmith; J McLaughlin; D Malkin
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

7.  Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.

Authors:  Kourosh M Naeini; Whitney B Pope; Timothy F Cloughesy; Robert J Harris; Albert Lai; Ascia Eskin; Reshmi Chowdhury; Heidi S Phillips; Phioanh L Nghiemphu; Yalda Behbahanian; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2013-02-26       Impact factor: 12.300

Review 8.  Genome-Wide Association Studies in Glioma.

Authors:  Ben Kinnersley; Richard S Houlston; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01-30       Impact factor: 4.254

9.  Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Authors:  Josie Hayes; Yao Yu; Llewellyn E Jalbert; Tali Mazor; Lindsey E Jones; Matthew D Wood; Kyle M Walsh; Henrik Bengtsson; Chibo Hong; Stefan Oberndorfer; Thomas Roetzer; Ivan V Smirnov; Jennifer L Clarke; Manish K Aghi; Susan M Chang; Sarah J Nelson; Adelheid Woehrer; Joanna J Phillips; David A Solomon; Joseph F Costello
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

10.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.